Impact of phenytoin therapy on the skin and skin disease

Expert Opinion on Drug Safety

Volumn 3, Issue 6, 2004, Pages 655-665

  Scheinfeld, Noah ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Dilantin; Fetal hydantoin syndrome (FHS); Gingival hyperplasia; Hypersensitivity syndrome; Phenytoin; Pseudolymphoma; Purple hand syndrome

Indexed keywords

ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; BIOTIN; CARBAMAZEPINE; COPPER; CORTICOSTEROID; FOSPHENYTOIN SODIUM; GABAPENTIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LAMOTRIGINE; MAGNESIUM; MALONALDEHYDE; MEPHENYTOIN; NORMEPHENYTOIN; PHENOBARBITAL; PHENYTOIN; SUPEROXIDE DISMUTASE; VALPROIC ACID; ZINC;

ACNE; ANGIONEUROTIC EDEMA; BLOOD CLOTTING; BRAIN SPONGIOSIS; BULLOUS SKIN DISEASE; COARSE FACE; DERMATOMYOSITIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; ENVIRONMENTAL EXPOSURE; EOSINOPHILIA; EXFOLIATIVE DERMATITIS; FACE EDEMA; FETAL HYDANTOIN SYNDROME; FEVER; FINGER MALFORMATION; FULMINATING PURPURA; GINGIVA HYPERPLASIA; GROWTH RETARDATION; HEPATOMEGALY; HIRSUTISM; HUMAN; IMMUNITY; LEUKOCYTOSIS; LIVER DYSFUNCTION; LONG TERM CARE; LYMPHADENOPATHY; LYMPHOCYTOSIS; LYMPHOMA; MONOCYTOSIS; MORBIDITY; MYCOSIS; MYCOSIS FUNGOIDES; NEUTROPHILIA; PIGMENT DISORDER; PORPHYRIA; PRESCRIPTION; PSEUDOLYMPHOMA; RASH; REVIEW; RIB MALFORMATION; SJOEGREN SYNDROME; SKIN DISEASE; STEVENS JOHNSON SYNDROME; STRUCTURE ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TOXIC EPIDERMAL NECROLYSIS; VASCULAR DISEASE; VASCULITIS;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTICONVULSANTS; CHILD; CONNECTIVE TISSUE DISEASES; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; EPILEPSY; FACIES; FEMALE; GINGIVAL HYPERPLASIA; HIRSUTISM; HUMANS; INFANT, NEWBORN; LYMPHOMA; MALE; MINERALS; PHENYTOIN; PREGNANCY; PREGNANCY COMPLICATIONS; PSEUDOLYMPHOMA; VASCULAR DISEASES; VITAMINS;

EID: 8844243217     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.6.655     Document Type: Review

References (139)

1. MERRITT HH, PUTNAM TJ: Sodium diphenylhydantoinate in the treatment of convulsive disorders. JAMA (1938) 111:1068-1073.
2. SILVERMAN AK, FAIRLEY J, WONG RC: Cutaneous and immunologic reactions to phenytoin. J. Am. Acad. Dermatol. (1988) 18 721-741.
3. SCHEINFELD N: Phenytoin in cutaneous medicine: its uses, mechanisms and side effects. Dermatol. Online J. (2003) 9 3):6.
4. OKAMOTO Y, SHIMIZU K, TAMURA K et al.: Effects of anticonvulsants on cellular immunity. No To Shinkei (1989) 41 299-304.
5. OKADA K, SUGIURA T, KURODA E, TSUJI S, YAMASHITA U: Phenytoin promotes Th2 type immune response in mice. Clin. Exp. Immunol. (2001) 124:406-413.
6. MARGARETTEN NC, HINCKS JR, WARREN RP, COULOMBE RA Jr: Effects of phenytoin and carbamazepine on human natural killer cell activity and genotoxicity in vitro. Toxicol. Appl. Pharmacol. (1987) 87 10-17.
7. PUTIGNANO P, KALTSAS GA, SATTA MA, GROSSMAN AB: The effects of anti-convulsant drugs on adrenal function. Horm. Metab. Res. (1998) 30:389-397.
8. RAPP RP, NORTON JA, YOUNG B, TIBBS PA: Cutaneous reactions in head-injured patients receiving phenytoin for seizure prophylaxis. Neurosurgery (1983) 13:272-375.
9. HEBERT AA, RALSTON JP: Cutaneous reactions to anticonvulsant medications. J. Clin. Psychiatry (2001) 62(Suppl. 14 ):22-26.
10. PELEKANOS J, CAMFIELD P, CAMFIELD C, GORDON K: Allergic rash due to antiepileptic drugs: clinical features and management. Epilepsia (1991) 32:554-559.
11. BEKELE G, ABEBE Y, T'HAIMANOT R: Plasma level distribution, effect and toxicity of antiepileptic drugs among Ethiopian epileptics. Ethiop. Med. J. (1990) 28:23-30.
12. JAIARJ N: Drug-induced gingival overgrowth. J. Mass. Dent. Soc. (2003) 52:16-20.
13. MARAKOGLU I, GURSOY UK, CAKMAK H, MARAKOGLU K: Phenytoin-induced gingival overgrowth in un-cooperated epilepsy patients. Yonsei Med. J. (2004) 45:337-340.
14. PRASAD VN, CHAWLA HS, GOYAL A, GAUBA K, SINGHI P: Incidence of phenytoin induced gingival overgrowth in epileptic children: a six month evaluation. J. Indian Soc. Pedod. Prev. Dent. (2002) 20 73-80.
15. BROWN RS, BEAVER WT, BOTTOMLEY WK: On the mechanism of drug-induced gingival hyperplasia. J. Oral Pathol. Med. (1991) 20:201-209.
16. MATTIOLI A, MAURO S, MENETTI L, ORLANDO S: Factors involved in gingival hyperplasia caused by diphenyl hydantoin. Minerva Stomatol. (1997) 46:525-532.
17. HOU LT: Synthesis of collagen and fibronectin in fibroblasts derived from healthy and hyperplastic gingivae. J. Formos. Med. Assoc. (1993) 92:367-372.
18. IACOPINO AM, DOXEY D, CUTLER CW et al.: Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible molecular mechanism of drug-induced gingival hyperplasia. J. Periodontol. (1997) 68:73-83.
19. ZHOU LX, PIHLSTROM B, HARDWICK JP, PARK SS, WRIGHTON SA, HOLTZMAN JL: Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia. Clin. Pharmacol. Ther. (1996) 60 191-198.
20. ROTHMEIER J, FROSCHER W: Connective tissue changes during long term anticonvulsive therapy. Fortschr. Med. (1989) 107 743-747.
21. LEFEBVRE EB, HAINING RG, LABBE RF: Coarse facies, calvarial thickening and hyperphosphatasia associated with long-term anticonvulsant therapy. N. Engl. J. Med. (1972) 286:1301-1302.
22. FALCONER MA, DAVIDSON S: Coarse features in epilepsy as a consequence of anticonvulsant therapy. Report of cases in two pairs of identical twins. Lancet (1973) 2:1112-1114.
23. JARAMILLO MJ, STEWART KJ, KOLHE PS: Phenytoin induced rhinophyma treated by excision and full thickness skin grafting. Br. J. Plast. Surg. (2000) 53:521-523.
24. HERBERG KP: Effects of diphenylhydantoin in 41 epileptics institutionalized since childhood. South. Med. J. (1977) 70 19-24.
25. LIVINGSTON S, PETERSON D, BOKS LL: Hypertrichosis occurring in association with Dilantin therapy. J. Pediatr. (1955) 47 351-352.
26. TREVISOL-BITTENCOURT PC, DA SILVA VR, MOLINARI MA, TROIANO AR: Phenytoin as the first option in female epileptic patients? Arq. Neuropsiquiatr. (1999) 57:784-786.
27. GREENWOOD R, FENWICK PB, CUNLIFFE WJ: Acne and anticonvulsants. Br. Med. J. (1983) 287:1669-1670.
28. WALLACE SJ: A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf. (1996) 15 378-393.
29. DACOSTA ML, REGAN MC, AL SADER M, LEADER M, BOUCHIER-HAYES D: Diphenylhydantoin sodium promotes early and marked angiogenesis and results in increased collagen deposition and tensile strength in healing wounds. Surgery (1998) 123:287-293.
30. KAUR S, GORAYA JS, THAMI GP, KANWAR AJ: Pellagrous dermatitis induced by phenytoin. Pediatr. Dermatol. (2002) 19:93.
31. HEBESTREIT H, PANNENBECKER J, MINGERS AM, BARTELS H: Pellagra in anticonvulsive therapy. Monatsschr. Kinderheilkd. (1990) 138 808-810.
32. MOCK DM: Skin manifestations of biotin deficiency. Semin. Dermatol. (1991) 10:296-302.
33. MOCK DM, MOCK NI, NELSON RP, LOMBARD KA: Disturbances in biotin metabolism in children undergoing long-term anticonvulsant therapy. J. Pediatr. Gastroenterol. Nutr. (1998) 26:245-250.
34. KRAUSE KH, BERLIT P, BONJOUR JP: Impaired biotin status in anticonvulsant therapy. Ann. Neurol. (1982) 12:485-486.
35. KRAUSE KH, BERLIT P, BONJOUR JP: Reduction of biotin level as a possible factor in the mode of action of anticonvulsants. Arch. Psychiatr. Nervenkr. (1982) 231:141-148.
36. KRAUSE KH, BONJOUR JP, BERLIT P, KOCHEN W: Biotin status of epileptics. Ann. N Y Acad. Sci. (1985) 447:297-313.
37. LEWIS DP, VAN DYKE DC, WILLHITE LA, STUMBO PJ, BERG MJ: Phenytoin-folic acid interaction. Ann. Pharmacother. (1995) 29 726-735.
38. SUZUKI T, KOIZUMI J, MOROJI T et al.: Effects of long-term anticonvulsant therapy on copper, zinc, and magnesium in hair and serum of epileptics. Biol. Psychiatry (1992) 31:571-581.
39. LIU CS, WU HM, KAO SH, WEI YH: Serum trace elements, glutathione, copper/zinc superoxide dismutase, and lipid peroxidation in epileptic patients with phenytoin or carbamazepine. Clin. Neuropharmacol. (1998) 21:62-64.
40. GHOSE K, TAYLOR A: Hypercupraemia induced by antiepileptic drugs. Hum. Toxicol. (1983) 2:519-529.
41. LEWIS-JONES MS, EVANS S, CULSHAW MA: Cutaneous manifestations of zinc deficiency during treatment with anticonvulsancs. Br. Med. J. (1985) 290:603-604.
42. KUZUYA T, HASEGAWA T, SHIMIZU K, NABESHIMA T: Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients. Int. J. Clin. Pharmacol. Ther. Toxicol. (1993) 31 61-65.
43. HOLDER SM, JOY MS, FALK RJ: Cutaneous and systemic manifestations of drug-induced vasculitis. Ann. Pharmacother. (2002) 36:130-147.
44. LEONG KP, CHNG HH: Allergic reactions to phenytoin in a general hospital in Singapore. Asian Pac. J. Allergy Immunol. (1996) 14:65-68.
45. SHARMA VK, DHAR S, GILL AN: Drug related involvement of specific sites in fixed eruptions: a statistical evaluation. J. Dermatol. (1996) 23:530-534.
46. GALINDO PA, BORJA J, GOMEZ E et al.:. Anticonvulsant drug hypersensitivity. J. Investig. Allergol. Clin. Immunol. (2002) 12:299-304.
47. SHARMA VK, VATVE M, SAWHNEY IM, KUMAR B: Clinical spectrum of drug rashes due to antiepileptics. J. Assoc. Physicians India (1998) 46:595-597.
48. MAQUIERA E, YANEZ S, FERNANDEZ L et al.: Mononucleosis-like illness as a manifestation of carbamazepine-induced anticonvulsant hypersensitivity syndrome. Allergol. Immunopathol. (1996) 24:87-88.
49. SHEAR NH, SPIELBERG SP: Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J. Clin. Invest. (1988) 82:1826-1832.
50. GRUNWALD MH, BEN-DOR D, LIVNI E, HALEVY S: Acne keloidalis-like lesions on the scalp associated with antiepileptic drugs. Int. J. Dermatol. (1990) 29:559-561.
51. COHEN AD, REICHENTAL E, HALEVY S: Phenytoin-induced severe cutaneous drug reactions: suspected interactions with corticosteroids and H2-blockers. Isr. Med. Assoc. J. (1999) 1:95-97.
52. MICALI G, LINTHICUM K, HAN N, WEST DP: Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Pharmacotherapy (1999) 19:223-227.
53. AHMED I, REICHENBERG J, LUCAS A, SHEHAN JM: Erythema multiforme associated with phenytoin and cranial radiation therapy: a report of three patients and review ofthe literature. Int. J. Dermatol. (2004) 43:67-73.
54. AGUIAR D, PAZO R, DURAN I et al.: Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J. Neurooncol. (2004) 66:345-350.
55. ALTUNTAS Y, OZTURK B, ERDEM L et al.: Phenytoin-induced toxic cholestatic hepatitis in a patient with skin lesions: case report. South. Med. J. (2003) 96:201-203.
56. KNOWLES SR, SHAPIRO LE, SHEAR NH: Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. (1999) 21:489-501.
57. MONKS G, CROWSON AN, CORNELISON R, NAYLOR M: A case of phenytoin hypersensitivity syndrome. J. Drugs Dermatol. (2002) 1 2):199-201.
58. KAUR S, SARKAR R, THAMI GP, KANWAR AJ: Anticonvulsant hypersensitivity syndrome. Pediatr. Dermatol. (2002) 19 142-145.
59. NAGAI Y, HATTORI T, ISHIKAWA O: A case of hypersensitivity syndrome due to phenytoin. J. Dermatol. (2002) 29:670-673.
60. FUJINO Y, NAKAJIMA M, INOUE H, KUSUHARA T, YAMADA T: Human herpesvirus 6 encephalitis associated with hypersensitivity syndrome. Ann. Neurol. (2002) 51:771-774.
61. AIHARA M, SUGITA Y, TAKAHASHI S et al.: Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br. J Dermatol. (2001) 144:1231-1234.
62. DANNO K, KUME M, OHTA M, UTANI A, OHNO S, KOBASHI Y: Erythroderma with generalized lymphadenopathy induced by phenytoin. J. Dermatol. (1989) 16:392-396.
63. POTTER T, DIGREGORIO F, STIFF M, HASHIMOTO K: Dilantin hypersensitivity syndrome imitating staphylococcal toxic shock. Arch. Dermatol. (1994) 130:856-858.
64. WEEDON AP: Diphenylhydantoin sensitivity: a syndrome resembling infectious mononucleosis with a morbilliform rash and cholestatic hepatitis. Aust. NZ J. Med. (1975) 5:561-563.
65. KLEIER RS, BRENEMAN DL, BOIKO S: Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch. Dermatol. (1991) 127:1361-1364.
66. STANLEY J, FALLON-PELLICCI V: Phenytoin hypersensitivity reaction. Arch. Dermatol. (1978) 114:135-153.
67. CHAIKEN BH, GOLDBERG BI, SEGAL JP: Dilantin sensitivity. Report of a case of hepatitis with jaundice, pyrexia, and exfoliative dermatitis. N. Engl. J. Med. (1950) 242:897-898.
68. HAMER HM, MORRIS HH: Successful treatment with gabapentin in the presence of hypersensitivity syndrome to phenytoin and carbamazepine: a report of three cases. Seizure (1999) 8:190-192.
69. BESSMERTNY O, PHAM T: Antiepileptic hypersensitivity syndrome: clinicians beware and be aware. Curr. Allergy Asthma Rep. (2002) 2:34-39.
70. MOSTELLA J, PIERONI R, JONES R, FINCH CK: Anticonvulsant hypersensitivity syndrome: treatment with corticosteroids and intravenous immunoglobulin. South. Med. J. (2004) 97:319-321.
71. LEEDER JS: Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia (1998) 39(Suppl. 7):S8-S16.
72. YOO JH, KANG DS, CHUN WH, LEE WJ, LEE AK: Anticonvulsant hypersensitivity syndrome with an epoxide hydrolase defect. Br. J. Dermatol. (1999) 140:181-183.
73. GAFFEY CM, CHUN B, HARVEY JC, MANZ HJ: Phenytoin-induced systemic granulomatous vasculitis. Arch. Pathol. Lab. Med. (1986) 110:131-135.
74. ROMERO MALDONADO N, SENDRA TELLO J, RABOSO GARCIA-BAQUERO, E, HARTO CASTANO A: Anticonvulsant hypersensitivity syndrome with fatal outcome. Eur. J. Dermatol. (2002) 12(5):503-505.
75. KRUSPE R, BROUSSARD A, SANTANILLA J et al.: Lymphoma or pseudolymphoma? J. La. State Med. Soc. (2002) 154:178-181; quiz 181-182.
76. ONO T, JOHNO M, KAYASHIMA K, OMORI A: Anticonvulsant syndrome with multiple symptoms, including porphyria, IgA deficiency, and liver dysfunction. J. Dermatol. (1990) 17:684-689.
77. KANWAR AJ, JASWAL R, THAMI GP, BEDI GK: Acquired acromelanosis due to phenytoin. Dermatology (1997) 194 373-374.
78. SMITH DA, BURGDORF WH: Universal cutaneous depigmentation following phenytoin-induced toxic epidermal necrolysis. J. Am. Acad. Dermatol. (1984) 10:106-109.
79. YANDEL ML, WATTERS MR: Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma. Clin. Neurol. Neurosurg. (1995) 97 261-263.
80. RUGGIAN JC, FISHBANE S, DEMENTO FJ, MAESAKA JK, FREI GL: Porphyria cutanea tarda in a patient on chronic ambulatory peritoneal dialysis. J. Am. Soc. Nephrol. (1996) 7:397-402.
81. FUCHS T, SEUBERT A, SEUBERT S, IPPEN H: Anticonvulsant-induced unclassified porphyria. Int. J. Biochem. (1980) 12:955-957.
82. BARZILAY D, ORION E, BRENNER S: Porphyria cutanea tarda triggered by a combination of three predisposing factors. Dermatology (2001) 203:195-197.
83. HERRICK AL, MCCOLL KE, MOORE MR, BRODIE MJ, ADAMSON AR, GOLDBERG A: Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity. Br. J. Clin. Pharmacol. (1989) 27 491-497.
84. HUNT SJ: Cutaneous necrosis and multinucleate epidermal cells associated with intravenous phenytoin. Am. J. Dermatopathol. (1995) 17:399-402.
85. KUECHLE MK, STEGEMEIR E, MAYNARD B, GIBSON LE, LEIFERMAN KM, PETERS MS: Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J. Am. Acad. Dermatol. (1994) 30:187-192.
86. SHARMA OP, KALKAT G: Drug induced clinical syndromes mimicking sarcoidosis. Sarcoidosis (1991) 8:3-5.
87. RUBINSTEIN I, BAUM GL, HISS Y, GOLDHAMMER Y: Does prolonged use of diphenylhydantoin predispose to pulmonary sarcoidosis? Eur. Neurol. (1986) 25:281-284.
88. KATTAN KR: Thickening of the heel-pad associated with long-term dilantin therapy. Am. J. Roentgenol. Radium Ther. Nucl. Med. (197) 124:52-56.
89. TRAN D, KOSSARD S, SHUMACK S: Phenytoin-induced linear IgA dermatosis mimicking toxic epidermal necrolysis. Australas. J. Dermatol. (2003) 44(4):284-286.
90. WEAVER DK: Atypical lymphadenopathies of the head and neck Crit. Rev. Clin. Lab. Sci. (1981) 15:1-24.
91. GAMS RA, NEAL JA, CONRAD FG: Hydantoin-induced pseudo-pseudolymphoma. Ann. Intern. Med. (1968) 69:557-568.
92. HARRIS DW, OSTLERE L, BUCKLEY C, WHITTAKER S, SWENY P, RUSTIN MH: Phenytoin-induced pseudolymphoma. A report of a case and review of the literature. Br. J. Dermatol. (1992) 127:403-406.
93. GREENE DA: Localized cervical lymphadenopathy induced by diphenylhydantoin sodium. Arch. Otolaryngol. (1975) 101 446-448.
94. SCHWINGHAMMER TL, HOWRIE DL: Phenytoin-induced lymphadenopathy. Drug Intell. Clin. Pharm. (1983) 17:460-462.
95. BRADDOCK SW, HARRINGTON D, VOSE J: Generalized nodular cutaneous pseudolymphoma associated with phenytoin therapy. Use of T-cell receptor gene rearrangement in diagnosis and clinical review of cutaneous reactions to phenytoin. J. Am. Acad. Dermatol. (1992) 27 337-340.
96. JENG YM, TIEN HF, SU IJ: Phenytoin-induced pseudolymphoma: reevaluation using modern molecular biology techniques. Epilepsia (1996) 37:104-107.
97. CHOI TS, DOH KS, KIM SH, JANG MS, SUH KS, KIM ST: Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome. Br. J. Dermatol. (2003) 148:730-736.
98. COOKE LE, HARDIN TC, HENDRICKSON DJ: Phenytoin-induced pseudolymphoma with mycosis fungoides manifestations. Clin. Pharm. (1988) 7:153-157.
99. ROSENTHAL CJ, NOGUERA CA, COPPOLA A, KAPELNER SN: Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation. Cancer (1982) 49:2305-2314.
100. RIJLAARSDAM U, SCHEFFER E, MEIJER CJ, KRUYSWIJK MR, WILLEMZE R: Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J. Am. Acad. Dermatol. (1991) 24 216-220.
101. WESTHOVEN GS, FRETZIN S, LEWIS C: A woman with lung cancer and exfoliative dermatitis. Phenytoin-induced pseudo-mycosis fungoides syndrome (PMFS). Arch. Dermatol. (1997) 133:499-502.
102. WOLF R, KAHANE E, SANDBANK M: Mycosis fungoides-like lesions associated with phenytoin therapy. Arch. Dermatol. (1985) 121 1181-1182.
103. ADAMS JD: Localized cutaneous pseudolymphoma associated with phenytoin therapy: a case report Australas. J. Dermatol. (1981) 22:28-29.
104. ABBONDAZO SL, IREY NS, FRIZZERA G: Dilantin-associated lymphadenopathy. Spectrum of histopathologic patterns. Am. J. Surg. Pathol. (1995) 19:675-686.
105. SORRELL TC, FORBES IJ: Phenytoin sensitivity in a case of phenytoin-associated Hodgkin's disease. Aust. NZ J. Med. (1975) 5:144-147.
106. LI FP, WILLARD DR, GOODMAN R, VAWTER G: Malignant lymphoma after diphenylhydantoin (dilantin) therapy. Cancer (1975) 36 1359-1362.
107. CHARLTON MH, LUSFORD D: Le sostanze di idantoina come possibili cause del linforma maligno. Minerva Med. (1971) 62 218. Italian.
108. ROSS S, ORMEROD AD, ROBERTS C: Subacute cutaneous lupus erythematosus associated with phenytoin. Clin. Exp. Dermatol. (2002) 27:474-476.
109. DIMACHKIE MM, VRIESENDORP FJ, HECK KA: Phenytoin-induced dermatomyositis: case report and literature review. J. Child Neurol. (1998) 13:577-580.
110. DRORY VE, KORCZYN AD: Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin. Neuropharmacol. (1993) 16:19-29.
111. GLEICHMAN H: Systemic lupus erythematous triggered by diphenylhydantoin. Arthritis Rheum. (1982) 25:1387-1388.
112. MANGALVEDHEKAR SS, GOGTAY NJ, MANJULA S et al.: Phenytoin associated alopecia: drug induced lupus. J. Assoc. Physicians India (2001) 49:929-930.
113. SINGSEN BH, FISHMAN L, HANSON V: Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants. Pediatrics (1976) 57:529-534.
114. ZANGEMEISTER WH, WEISNER B: A progressive systemic sclerosis like disease due to anticonvulsive therapy? Fortschr. Neurol. Pychiatr. Grenzgeb (1977) 45:501-507.
115. KASHIWAZAKI S, GOTO T, OKADA J, TADENUMA T, TAZAKI Y: Scleroderma developing during treatment of ictal stupor with diphenylhydantoin. Ryumachi (1974) 14:220-228.
116. CHAKRAVARTY K, AL-JAFARI MS: Phenytoin-induced pseudo-Sjogren's syndrome. Br. J. Rheumatol. (1996) 35 1033-1034.
117. TARGAN SR, CHASSIN MR, GUZE LB: Dilantin-induced disseminated intravascular coagulation with purpura fulminans. A case report. Ann. Intern. Med. (1975) 83:227-230.
118. HANUKOGLU A, FRIED D, GOTLIEB A: Dyphenylhydantoin induced hypersensitivity reaction with an unusual purpuric skin lesion. Eur. J. Pediatr. (1980) 134:177-179.
119. ZIDAR BL, MENDELOW H, WINKELSTEIN A, SHADDUCK AK: Diphenylhydantoin-induced serum sickness with fibrin-platelet thrombi in lymph node microvasculature. Am. J. Med. (1975) 58:704-708.
120. HARRISON RL, ALPERIN JB, KUMAR D: Concurrent lupus anticoagulants and prothrombin deficiency due to phenytoin use. Arch. Pathol. Lab. Med. (1987) 111:719-722.
121. HOWE AM, LIPSON AH, SHEFFIELD LJ et al.: Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Am. J. Med. Genet. (1995) 58:238-244.
122. HEY E: Effect of maternal anticonvulsant treatment on neonatal blood coagulation. Arch. Dis. Child. Fetal Neonatal Ed. (1999) 81:F208-F210.
123. SCHMUTZ J, BARBAUD A, TRECHOT P: Purple hand syndrome and intravenous phenytoine. Ann. Dermatol. Venereol. (2000) 127 548.
124. BURNEO JG, ANANDAN JV, BARKLEY GL: A prospective study of the incidence of the purple glove syndrome. Epilepsia (2001) 42 1156-1159.
125. O'BRIEN TJ, CASCINO GD, SO EL, HANNA DR: Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology (1998) 51:1034-1039.
126. O'BRIEN TJ, MEARA FM, MATTHEWS H, VAJDA FJ: Prospective study of local cutaneous reactions in patients receiving IV phenytoin. Neurology (2001) 57:1508-1510.
127. JAMERSON BD, DUKES GE, BROUWER KL, DONN KH, MESSENHEIMER JA, POWELL JR: Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy (1994) 14 47-52.
128. KNAPP LE, KUGLER AR: Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. J. Child Neurol. (1998) 13(Suppl. 1):S15-S18; discussion S30-32.
129. RAMSAY RE, DETOLEDO J: Intravenous administration of fosphenytoin: options for the management of seizures. Neurology (1996) 46(6 Suppl. 1):S17-S19.
130. MOORE SJ, TURNPENNY P, QUINN A et al.: A clinical study of 57 children with fetal anticonvulsant syndromes. J. Med. Genet. (2000) 37(7):489-497.
131. JOHNSON RB, GOLDSMITH LA: Dilantin digital defects. J. Am. Acad. Dermatol. (1981) 5:191-196.
132. NANDA A, KAUR S, BHAKOO ON, KAPOOR MM, KANWAR AJ: Fetal hydantoin syndrome: a case report. Pediatr. Dermatol. (1989) 6 130-133.
133. VERDEGUER JM, RAMON D, MORAGON M, BETLLOCH I, JORDA E, PLANELLES MV: Onychopathy in a patient with fetal hydantoin syndrome. Pediatr. Dermatol. (1988) 5:56-57.
134. STANKLER L, CAMPBELL AG: Neonatal acne vulgaris: a possible feature of the fetal hydantoin syndrome. Br. J. Dermatol. (1980) 103:453-455.
135. DE SMET L, DEBEER P: Fetal hydantoin syndrome with unilateral atypical cleft hand: additional evidence for vascular disruption. Genet. Couns. (2002) 13:157-161.
136. FRIS ML, BROENG-NIELSEN B, SINDRUP EH, LUND M, FOGH-ANDERSEN P, HAUGE M: Facial clefts among epileptic patients. Arch. Neurol. (1981) 38:227-229
137. FRIIS ML, HOLM NV, SINDRUP EH, FOGH-ANDERSEN P, HAUGE M: Facial clefts in sibs and children of epileptic patients. Neurology (1986) 36:346-350.
138. OWENS JR, JONES JW, HARRIS F: Epidemiology of facial clefting. Arch. Dis. Child (1985) 60:521-524.
139. FRIIS ML: Facial clefts and congenital heart defects in children of parents with epilepsy: genetic and environmental etiologic factors. Acta Neurol. Scand. (1989) 79:433-459.